Are Foundayo and Rybelsus interchangeable?

No. Different active ingredients, different approved uses: Foundayo for weight management, Rybelsus for type 2 diabetes. Each label also recommends against combining its product with any other GLP-1 receptor agonist.

Why does Rybelsus need an empty stomach and Foundayo does not?

The labels do not explain each other; they simply state different instructions. The Rybelsus document requires the empty stomach, plain water and a 30-minute wait; the Foundayo document allows taking it with or without food.

Is there a semaglutide tablet for weight loss?

The Rybelsus label covers type 2 diabetes, not weight. Semaglutide's weight approval is the Wegovy injection. Whether other semaglutide tablet products hold approvals is a question for the FDA register; this catalog covers the labels listed on its pages.

Weight lossTwo labels compared

Foundayo vs Rybelsus

Foundayo and Rybelsus are the two GLP-1 tablets, and that is where the similarity ends. They contain different molecules, hold different approvals, and read completely differently on how to take them: the Rybelsus label is built around an empty stomach and a timed wait, the Foundayo label says with or without food. This page sets the two documents side by side.

Foundayo

Ingredient: Orforglipron
Approved for: Weight managementcovers weight loss
Supply: Prescription
Boxed warning: WARNING: RISK OF THYROID C-CELL TUMORS
Pharmacy cost: $20.65 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter

Eli Lilly and Company. Label version 10, effective 29 July 2026.

Rybelsus and Ozempic tablets

Ingredient: Semaglutide
Approved for: Type 2 diabetesnot weight loss
Supply: Prescription
Boxed warning: WARNING: RISK OF THYROID C-CELL TUMORS
Pharmacy cost: $33.17 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter

Novo Nordisk Pharmaceutical Industries, LP. Label version 13, effective 30 January 2026.

01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Label section	FoundayoOrforglipron	Rybelsus and Ozempic tabletsSemaglutide
Active ingredient	FoundayoOrforglipronGLP-1 receptor agonist	Rybelsus and Ozempic tabletsSemaglutideGLP-1 receptor agonist
Approved for	FoundayoWeight management	Rybelsus and Ozempic tabletsType 2 diabetes
Supplysame in both	FoundayoPrescription	Rybelsus and Ozempic tabletsPrescription
What pharmacies payAcquisition cost, not retail	Foundayo$20.65 per tablet, capsule or pen, brand	Rybelsus and Ozempic tablets$33.17 per tablet, capsule or pen, brand
Boxed warningsame in both	FoundayoWARNING: RISK OF THYROID C-CELL TUMORS	Rybelsus and Ozempic tabletsWARNING: RISK OF THYROID C-CELL TUMORS
What the FDA approved it for	Foundayo FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.	Rybelsus and Ozempic tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Forms and strengths	Foundayo FOUNDAYO tablets are available as orforglipron: 0.8 mg: pink round tablet debossed with "L" on one side and "G1" on the other side 2.5 mg: light yellow round tablet debossed with "L" on one side and "G2" on the other side 5.5 mg: grayish purple round tablet debossed with "L" on one side and "G3" on the other side 9 mg: pink modified oval tablet debossed with "Lilly" on one side and "G4" on the...	Rybelsus and Ozempic tablets RYBELSUS tablets: 3 mg, 7 mg and 14 mg OZEMPIC tablets: 1.5 mg, 4 mg and 9 mg
How the label says it is taken	Foundayo Take FOUNDAYO orally once daily, with or without food. Swallow tablets whole. Do not break, crush, or chew. Do not take more than one tablet per day. Starting dosage is 0.8 mg once daily. After at least 30 days, increase dosage to 2.5 mg once daily. After at least 30 days on the 2.5 mg dosage, increase dosage to 5.5 mg once daily. Dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability.	Rybelsus and Ozempic tablets Take RYBELSUS or OZEMPIC tablets orally once daily on an empty stomach in the morning with water (up to 4 ounces of water); do not take with other liquids besides water. Swallow tablets whole. Do not split, crush, chew or dissolve in any solution. After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications. See the Full Prescribing Information for instructions on switching between RYBELSUS and OZEMPIC tablets and from OZEMPIC injections to RYBELSUS or OZEMPIC tablets. Recommended Starting, Escalation and Maintenance Dosage of RYBELSUS and OZEMPIC Tablets RYBELSUS On Day 61 or thereafter, if: No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily.; Additional glycemic control is needed, increase the dosage to 14 mg orally once daily. OZEMPIC Tablets
Most common adverse reactions	Foundayo Most common adverse reactions, reported in ≥5% of patients treated with FOUNDAYO, are nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss.	Rybelsus and Ozempic tablets Most common adverse reactions (incidence ≥5%) are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation.
Warnings and precautions	Foundayo Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including FOUNDAYO. Discontinue if pancreatitis is suspected. Severe Gastrointestinal Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. FOUNDAYO is not recommended in patients with severe gastroparesis. Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If suspected, advise the patient to promptly seek medical attention and discontinue FOUNDAYO. Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Monitor patients with a history of diabetic retinopathy for progression. Acute Gallbladder Disease: Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated. Pulmonary Aspiration During General Anesthesia and Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures.	Rybelsus and Ozempic tablets Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS or OZEMPIC tablets. Discontinue if pancreatitis is suspected. Diabetic Retinopathy Complications: Has been reported in a cardiovascular outcomes trial with semaglutide injection. Patients with a history of diabetic retinopathy should be monitored. Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: May increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin secretagogue or insulin may be necessary. Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. Severe Gastrointestinal Adverse Reactions: Use of RYBELSUS or OZEMPIC tablets has been associated with gastrointestinal adverse reactions, sometimes severe. RYBELSUS and OZEMPIC tablets are not recommended in patients with severe gastroparesis. Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue RYBELSUS or OZEMPIC tablets if hypersensitivity reactions occur and monitor until signs and symptoms resolve. Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated. Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures.
Contraindications	Foundayo FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2. Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists. Personal or family history of MTC or in patients with MEN 2	Rybelsus and Ozempic tablets Personal or family history of MTC or in patients with MEN 2 syndrome type 2 Prior serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC
Drug interactions	Foundayo Strong CYP3A4 Inhibitors: The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use with strong CYP3A4 inhibitors that also inhibit OATP1B. CYP3A4 Inducers: Avoid concomitant use with strong CYP3A4 inducers. Monitor FOUNDAYO effectiveness and escalate dosage as needed when used concomitantly with moderate CYP3A4 inducers. Simvastatin: Do not exceed simvastatin 20 mg once daily when used concomitantly with FOUNDAYO. FOUNDAYO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications.	Rybelsus and Ozempic tablets Other Oral Drugs: RYBELSUS and OZEMPIC tablets delay gastric emptying. Consider increased clinical or laboratory monitoring when co-administered with other oral medications that have a narrow therapeutic index or that require clinical monitoring.
Label version	Foundayo29 July 2026	Rybelsus and Ozempic tablets30 January 2026

02Written by us

Different molecules, different approved uses

Foundayo is orforglipron, approved to reduce excess body weight and maintain that reduction long term in adults with obesity or with overweight plus a weight-related condition. Rybelsus is semaglutide, approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Neither label lists the other's use.

03Written by us

The dosing rules are the practical difference

The Rybelsus label instructs: take once daily on an empty stomach in the morning, with up to 4 ounces of plain water only, then wait at least 30 minutes before eating, drinking or taking other oral medications.

The Foundayo label instructs: take once daily, with or without food, swallowing the tablet whole. No fasting window and no waiting period appear in it.

04Written by us

The class warnings are shared

Both carry the boxed warning on thyroid C-cell tumors with the contraindication for medullary thyroid carcinoma history and MEN 2, and both warn against use with another GLP-1 receptor agonist.

05Written by us

What this page does not tell you

It does not say which tablet a person should take: the two are approved for different conditions, and prescribing outside an approved use is a clinician's decision that this page does not describe.

06Written by us

Common questions

Are Foundayo and Rybelsus interchangeable?: No. Different active ingredients, different approved uses: Foundayo for weight management, Rybelsus for type 2 diabetes. Each label also recommends against combining its product with any other GLP-1 receptor agonist.
Why does Rybelsus need an empty stomach and Foundayo does not?: The labels do not explain each other; they simply state different instructions. The Rybelsus document requires the empty stomach, plain water and a 30-minute wait; the Foundayo document allows taking it with or without food.
Is there a semaglutide tablet for weight loss?: The Rybelsus label covers type 2 diabetes, not weight. Semaglutide's weight approval is the Wegovy injection. Whether other semaglutide tablet products hold approvals is a question for the FDA register; this catalog covers the labels listed on its pages.

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

FDA prescribing information for Foundayo
Eli Lilly and Company. Label version 10, effective 29 July 2026.
Full label on DailyMed Approval record NDA220934
FDA prescribing information for Rybelsus and Ozempic tablets
Novo Nordisk Pharmaceutical Industries, LP. Label version 13, effective 30 January 2026.
Full label on DailyMed Approval record NDA213051

Each stripe is one section of the label, each division in a stripe one entry in that section. The red bar marks a boxed warning.

Other comparisons in this category

Page last updated 29 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.